Genfit SA
GNFT4.850USD
0.0000.00%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
242.51MMarket Cap
--P/E TTM
More Details of Genfit SA Company
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Genfit SA Info
Ticker SymbolGNFT
Company nameGenfit SA
IPO dateDec 19, 2006
CEOPrigent (Pascal)
Number of employees180
Security typeDepository Receipt
Fiscal year-endDec 19
AddressParc Eurasante 885 avenue Eugene Avinee
CityLOOS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code59120
Phone33320164000
Websitehttps://www.genfit.fr/
Ticker SymbolGNFT
IPO dateDec 19, 2006
CEOPrigent (Pascal)
Company Executives of Genfit SA
Name
Name/Position
Position
Shareholding
Change
Mr. Jean-Francois Mouney
Mr. Jean-Francois Mouney
Chairman of the Board of Directors
Chairman of the Board of Directors
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Prof. Laurent Lannoo
Prof. Laurent Lannoo
Corporate Secretary, Director of Legal Affairs
Corporate Secretary, Director of Legal Affairs
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Mrs. Anne-Helene Monsellato
Mrs. Anne-Helene Monsellato
Independent Director
Independent Director
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Eric Baclet
Mr. Eric Baclet
Independent Vice-Chairman of the Board of Directors
Independent Vice-Chairman of the Board of Directors
--
--
Mr. Jean-Christophe Marcoux
Mr. Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jean-Francois Mouney
Mr. Jean-Francois Mouney
Chairman of the Board of Directors
Chairman of the Board of Directors
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Prof. Laurent Lannoo
Prof. Laurent Lannoo
Corporate Secretary, Director of Legal Affairs
Corporate Secretary, Director of Legal Affairs
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AllianceBernstein L.P.
0.04%
Morgan Stanley & Co. International Plc
0.04%
Summit Financial, LLC
0.04%
Other
99.88%
Shareholders
Shareholders
Proportion
AllianceBernstein L.P.
0.04%
Morgan Stanley & Co. International Plc
0.04%
Summit Financial, LLC
0.04%
Other
99.88%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
0.04%
Research Firm
0.04%
Investment Advisor
0.04%
Other
99.88%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
18
61.48K
0.12%
-644.21K
2025Q3
20
80.73K
0.16%
-686.95K
2025Q2
22
234.11K
0.47%
-547.30K
2025Q1
25
259.00K
0.52%
-1.29M
2024Q4
26
260.49K
0.52%
-1.21M
2024Q3
28
127.35K
0.26%
-1.36M
2024Q2
31
97.15K
0.20%
-1.36M
2024Q1
31
97.93K
0.20%
-1.42M
2023Q4
31
648.17K
1.30%
-1.34M
2023Q3
32
1.16M
2.33%
-1.43M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AllianceBernstein L.P.
22.36K
0.04%
+13.37K
+148.83%
Jun 30, 2024
Morgan Stanley & Co. International Plc
20.12K
0.04%
-7.30K
-26.62%
Sep 30, 2025
Summit Financial, LLC
18.75K
0.04%
+18.75K
--
Sep 30, 2025
Osaic Holdings, Inc.
225.00
0%
--
--
Sep 30, 2025
Principal Securities Inc
24.00
0%
--
--
Sep 30, 2025
Qube Research & Technologies Ltd
--
0%
-98.00
-100.00%
Sep 30, 2024
BofA Global Research (US)
--
0%
-1.00
-100.00%
Sep 30, 2025
Millennium Management LLC
--
0%
-131.48K
-100.00%
Jun 30, 2025
Lazard Asset Management, L.L.C.
--
0%
-3.30K
-100.00%
Jun 30, 2025
Geode Capital Management, L.L.C.
--
0%
-3.21K
-100.00%
Nov 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
